TickerGuard
Buy Day today: Neutral (46) Mixed market breadth · no major macro event
CVKD

Cadrenal Therapeutics, Inc.

Healthcare · Biotechnology

0.985$ +4.4% vs. previous close Closing price · As of: Oct 30, 2026

Ownership

Ownership Structure

Who owns Cadrenal Therapeutics, Inc. (CVKD)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 90.3% of the shares are freely tradable; institutional investors hold 6.0%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 6.0%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 16.0%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 90.3%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 3.3%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 3Mio.

Largest Shareholders

Institutions

Institutions CVKD
Name Stake (%) Shares Change (%) Date
Vanguard Capital Management, LLC 1.41 50,137 +10.9 06/30/2026
HRT FINANCIAL LLC 0.81 29,055 +0.0 06/30/2026
Geode Capital Management, LLC 0.53 19,024 -12.0 06/30/2026
Vanguard Fiduciary Trust Co 0.23 8,311 +0.0 06/30/2026
Tower Research Capital LLC 0.04 1,282 +226.2 06/30/2026
UBS Group AG 0.03 1,112 +36,966.7 06/30/2026

Funds

Funds CVKD
Name Stake (%) Shares Change (%) Date
Abante Quant Value FI 0.36 12,949 +0.0 08/31/2026
Fidelity Extended Market Index 0.34 12,241 -0.5 08/31/2026
Fidelity Series Total Market Index 0.07 2,449 +0.0 08/31/2026
Fidelity Nasdaq Composite Index 0.06 2,041 +0.0 08/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: October 30, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?